Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardian Pharmacy Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011826), on January 13, 2026, and is solely responsible for the information contained therein.